A M Brennan1, T Y Li, I Kelesidis, A Gavrila, F B Hu, C S Mantzoros. 1. Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02215, USA.
Abstract
AIMS/HYPOTHESIS: Leptin, an adipocyte-secreted hormone, plays an important role in regulating neuroendocrine and immune function as well as insulin resistance and metabolism. Our objective was to examine the relationship between leptin levels and cardiovascular morbidity and overall mortality in women with type 2 diabetes. SUBJECTS AND METHODS: This prospective cohort study included 1,194 women with a confirmed diagnosis of type 2 diabetes, who provided a blood sample at baseline in 1989-1990. Participants were followed for 12 years for the development of health outcomes including cardiovascular disease (CVD) events as well as total mortality. RESULTS: There were 218 new CVD events and 228 deaths from all causes. Cox proportional hazards analysis was used to estimate the relative risks (RRs) for each quintile level of leptin compared with the lowest quintile. Leptin levels were positively associated with several CVD risk factors including BMI and inflammatory markers, but were not independently associated with the incidence of CVD or total mortality in women with diabetes. The multivariate RRs (95% CIs) for CVD across the quintiles of leptin were 0.96 (0.61-1.53), 0.99 (0.61-1.61), 1.04 (0.63-1.71), 1.02 (0.59-1.75) (p for trend = 0.83). CONCLUSIONS/ INTERPRETATION: Although circulating leptin levels are associated with obesity and inflammatory markers, they are not significantly related to the risk of CVD or mortality in women with diabetes.
AIMS/HYPOTHESIS: Leptin, an adipocyte-secreted hormone, plays an important role in regulating neuroendocrine and immune function as well as insulin resistance and metabolism. Our objective was to examine the relationship between leptin levels and cardiovascular morbidity and overall mortality in women with type 2 diabetes. SUBJECTS AND METHODS: This prospective cohort study included 1,194 women with a confirmed diagnosis of type 2 diabetes, who provided a blood sample at baseline in 1989-1990. Participants were followed for 12 years for the development of health outcomes including cardiovascular disease (CVD) events as well as total mortality. RESULTS: There were 218 new CVD events and 228 deaths from all causes. Cox proportional hazards analysis was used to estimate the relative risks (RRs) for each quintile level of leptin compared with the lowest quintile. Leptin levels were positively associated with several CVD risk factors including BMI and inflammatory markers, but were not independently associated with the incidence of CVD or total mortality in women with diabetes. The multivariate RRs (95% CIs) for CVD across the quintiles of leptin were 0.96 (0.61-1.53), 0.99 (0.61-1.61), 1.04 (0.63-1.71), 1.02 (0.59-1.75) (p for trend = 0.83). CONCLUSIONS/ INTERPRETATION: Although circulating leptin levels are associated with obesity and inflammatory markers, they are not significantly related to the risk of CVD or mortality in women with diabetes.
Authors: Jennifer H Lee; Jean L Chan; Epaminondas Sourlas; Vassilios Raptopoulos; Christos S Mantzoros Journal: J Clin Endocrinol Metab Date: 2006-04-24 Impact factor: 5.958
Authors: Javier Gómez-Ambrosi; Javier Salvador; Camilo Silva; Fernando Rotellar; María J Gil; Javier A Cienfuegos; Gema Frühbeck Journal: J Clin Endocrinol Metab Date: 2005-06 Impact factor: 5.958
Authors: S Söderberg; B Ahrén; B Stegmayr; O Johnson; P G Wiklund; L Weinehall; G Hallmans; T Olsson Journal: Stroke Date: 1999-02 Impact factor: 7.914
Authors: J E Manson; G A Colditz; M J Stampfer; W C Willett; A S Krolewski; B Rosner; R A Arky; F E Speizer; C H Hennekens Journal: Arch Intern Med Date: 1991-06
Authors: J K Howard; G M Lord; G Matarese; S Vendetti; M A Ghatei; M A Ritter; R I Lechler; S R Bloom Journal: J Clin Invest Date: 1999-10 Impact factor: 14.808
Authors: Javier Gómez-Ambrosi; Javier Salvador; Jose A Páramo; Josune Orbe; Jokin de Irala; Alberto Diez-Caballero; María J Gil; Javier A Cienfuegos; Gema Frühbeck Journal: Clin Biochem Date: 2002-06 Impact factor: 3.281
Authors: I Sadaf Farooqi; Giuseppe Matarese; Graham M Lord; Julia M Keogh; Elizabeth Lawrence; Chizo Agwu; Veronica Sanna; Susan A Jebb; Francesco Perna; Silvia Fontana; Robert I Lechler; Alex M DePaoli; Stephen O'Rahilly Journal: J Clin Invest Date: 2002-10 Impact factor: 14.808
Authors: Ivy A Ku; Ramin Farzaneh-Far; Eric Vittinghoff; Mary H Zhang; Beeya Na; Mary A Whooley Journal: Atherosclerosis Date: 2010-12-02 Impact factor: 5.162
Authors: Nieves Gómez-Hurtado; Alejandro Domínguez-Rodríguez; Philippe Mateo; María Fernández-Velasco; Almudena Val-Blasco; Rafael Aizpún; Jessica Sabourin; Ana María Gómez; Jean-Pierre Benitah; Carmen Delgado Journal: J Physiol Date: 2017-05-23 Impact factor: 5.182
Authors: Eva Pardina; Roser Ferrer; Juan Antonio Baena-Fustegueras; Albert Lecube; Jose Manuel Fort; Víctor Vargas; Roberto Catalán; Julia Peinado-Onsurbe Journal: Obes Surg Date: 2010-05 Impact factor: 4.129
Authors: Hamidreza Saber; Jayandra J Himali; Ashkan Shoamanesh; Alexa Beiser; Aleksandra Pikula; Tamara B Harris; Ronenn Roubenoff; Jose Rafael Romero; Carlos S Kase; Ramachandran S Vasan; Sudha Seshadri Journal: Stroke Date: 2015-09-03 Impact factor: 7.914
Authors: Priscila L Sanches; Marco T de Mello; Natália Elias; Francisco A H Fonseca; Raquel M S Campos; June Carnier; Aline de Piano; Deborah C L Masquio; Patrícia L Silva; Lila M Oyama; Flavia C Corgosinho; Cláudia M O Nascimento; Lian Tock; Carolina Ackel D'Elia; Sergio Tufik; Ana R Dâmaso Journal: Inflammation Date: 2014-02 Impact factor: 4.092